OPK Key Statistics, Chart & Performance
The current stock price of OPK is 1.305 USD. In the past month the price decreased by -5.19%. In the past year, price decreased by -12.93%.
OPK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.84 | 102.92B | ||
| CI | THE CIGNA GROUP | 10.13 | 76.86B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 131.33 | 24.16B | ||
| LH | LABCORP HOLDINGS INC | 16.26 | 21.33B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.24 | 19.81B | ||
| GH | GUARDANT HEALTH INC | N/A | 14.39B | ||
| DVA | DAVITA INC | 12.38 | 8.06B | ||
| HIMS | HIMS & HERS HEALTH INC | 65.31 | 8.03B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 39.11 | 7.19B | ||
| CHE | CHEMED CORP | 19.9 | 6.20B | ||
| RDNT | RADNET INC | 202.58 | 5.94B | ||
| OPCH | OPTION CARE HEALTH INC | 21.87 | 5.17B |
Related stock screener links
About OPK
Company Profile
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,997 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Company Info
OPKO HEALTH INC
4400 Biscayne Blvd.
Miami FLORIDA 33137 US
CEO: Phillip Frost
Employees: 2997
Phone: 13055754181
OPKO HEALTH INC / OPK FAQ
Can you describe the business of OPKO HEALTH INC?
OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,997 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
What is the stock price of OPKO HEALTH INC today?
The current stock price of OPK is 1.305 USD. The price increased by 1.95% in the last trading session.
Does OPK stock pay dividends?
OPK does not pay a dividend.
What is the ChartMill technical and fundamental rating of OPK stock?
OPK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does OPKO HEALTH INC belong to?
OPKO HEALTH INC (OPK) operates in the Health Care sector and the Health Care Providers & Services industry.
Should I buy OPK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OPK.
OPK Technical Analysis
OPK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OPK. The financial health of OPK is average, but there are quite some concerns on its profitability.
OPK Financial Highlights
Over the last trailing twelve months OPK reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 19.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.04% | ||
| ROE | -13.82% | ||
| Debt/Equity | 0.26 |
OPK Forecast & Estimates
11 analysts have analysed OPK and the average price target is 3.74 USD. This implies a price increase of 186.85% is expected in the next year compared to the current price of 1.305.
For the next year, analysts expect an EPS growth of -57.34% and a revenue growth -12.67% for OPK